Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 1 |
2016 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Br J Haematol. 2021 Jul;194(2):298-308. doi: 10.1111/bjh.17501. Epub 2021 May 7.
Br J Haematol. 2021.
PMID: 33961292
Clinical Trial.
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. ...Despite promising pre-clinical, early non-randomised clinical data with acceptable toxicity and an improvement in response, we did not find evidence …
Older patients with acute myeloid leukaemia (AML) account for nearly half of those with the disease. ...Despite …
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH; UK National Cancer Research Institute AML Working Group.
Burnett AK, et al.
Leukemia. 2013 Jan;27(1):75-81. doi: 10.1038/leu.2012.229. Epub 2012 Aug 14.
Leukemia. 2013.
PMID: 22964882
Clinical Trial.
The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensive therapy, is unsatisfactory. ...
The treatment of older patients with acute myeloid leukaemia, who are not considered suitable for conventional intensiv …
Item in Clipboard
Assessment of Minimal Residual Disease in Standard-Risk AML.
Hills RK, Ivey A, Grimwade D; UK National Cancer Research Institute (NCRI) AML Working Group.
Hills RK, et al.
N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847.
N Engl J Med. 2016.
PMID: 27509124
Free article.
No abstract available.
Item in Clipboard
Cite
Cite